Photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Should Baseline Characteristics Affect Choice of Treatment?

Susan B. Bressler, Wesley T. Beaulieu, Adam R. Glassman, Jeffrey G. Gross, Michele Melia, Eric Chen, Michael R. Pavlica, Lee M. Jampol

Research output: Contribution to journalArticle

Abstract

Purpose:Among eyes with proliferative diabetic retinopathy, identify whether baseline characteristics impact the benefit of ranibizumab over panretinal photocoagulation (PRP) in DRCR.net Protocol S.Methods:Participants had proliferative diabetic retinopathy, visual acuity of 20/320 or better, and no previous PRP. Eyes were randomized to PRP or intravitreous 0.5-mg ranibizumab.Results:Ranibizumab was superior to PRP for change in visual acuity and development of vision-impairing central-involved diabetic macular edema over 2 years (P < 0.001). Among 25 characteristics, there were none in which participants assigned to PRP had superior outcomes relative to ranibizumab-Assigned participants. The relative benefit of ranibizumab over PRP for change in visual acuity seemed greater in participants with higher mean arterial pressure (P = 0.03), without previous focal/grid laser (P = 0.03), with neovascularization of the disk and elsewhere on clinical examination (P = 0.04), and with more advanced proliferative diabetic retinopathy on photographs (P = 0.02). For development of vision-impairing central-involved diabetic macular edema, the relative benefit of ranibizumab over PRP seemed greater among nonwhite participants (P = 0.01) and those with higher mean arterial pressure (P = 0.01).Conclusion:There were no characteristics identified in which outcomes were superior with PRP compared with ranibizumab. These exploratory analyses provide additional support that ranibizumab may be a reasonable alternative to PRP for proliferative diabetic retinopathy over a 2-year period.

Original languageEnglish (US)
Pages (from-to)1646-1654
Number of pages9
JournalRetina
Volume39
Issue number9
DOIs
StatePublished - Sep 1 2019

Keywords

  • photocoagulation
  • proliferative diabetic retinopathy
  • ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Should Baseline Characteristics Affect Choice of Treatment?'. Together they form a unique fingerprint.

  • Cite this